

BrainsWay Deep TMS™ for Smoking Addiction



**Smoking
Addiction**

The first noninvasive brain stimulation technology FDA-cleared to safely and effectively help patients overcome smoking addiction.



A Significant Unmet Need Exists in the Treatment of Smoking Addiction

- Prescription medications and nicotine replacement therapies (NRTs) do not work for many smokers, and present a wide range of debilitating side effects.
- Support groups and psychotherapy have limited success and are best implemented as adjunctive therapy to medication.



BrainsWay®

www.brainsway.com


BrainsWay Offers a New Tool to Treat Smokers Using Cutting-Edge Neuroscience

Deep TMS has significant advantages that address the limitations of traditional smoking addiction treatments.

- Clinically proven to help many patients who have previously failed to quit on Varenicline, Bupropion, NRTs, and psychotherapy
- Has none of the systemic side effects associated with medication
- Does not require self-monitoring of nicotine dosage

Deep TMS Treatment Stimulates Craving Centers Using the H4 Coil


- Treatment targets neurons in brain structures associated with addiction—specifically the bilateral insula and prefrontal cortex.




BrainsWay Deep TMS was Demonstrated Safe and Effective for Smoking Addiction in a Large Scale, Double-Blinded, Multicenter Randomized Controlled Trial

Study participants were highly addicted to smoking and treatment-resistant.

- **Nearly 1 in 3 patients** that completed 18 sessions achieved **4 or more weeks of abstinence (CQR)**.
- **2 of 3 patients** who quit smoking after completing treatment, **remained abstinent for at least an additional 3 months**.



- The **average number of cigarettes smoked** per week **decreased** among the active treatment group **by 75%, from 128 to 32**.
- **Cigarette craving and consumption** were **significantly reduced** by as early as the 2nd week of treatment.



- **No statistical difference was seen in adverse events** between the Deep TMS and Sham groups and no seizures were observed.



Offering Deep TMS for Smoking Addiction Positions You as a Leader in Brain Stimulation and Addiction Treatment in Your Community

BrainsWay's Practice Development Consultants work closely with you to build data-driven referral networks and optimize practice workflow, helping ensure a strong return-on-investment.

Learn more about offering Deep TMS treatment for Smoking Addiction in your practice

- ✓ **SPEAK** with a **BrainsWay representative**
- ✓ **SCAN** the **QR code** for more information
- ✓ **VISIT** the Knowledge Center at www.brainsway.com
- ✓ **CALL** us at **844-386-7001**
- ✓ **EMAIL** us at DeepTMS@brainsway.com



INDICATION: BrainsWay Deep TMS is indicated by the FDA as an aid in short-term smoking cessation for adults. FDA 510(k) No. K200957

SAFETY INFORMATION: Patients should consult with their doctor before undergoing BrainsWay Deep TMS. The most common side effects include headaches and application site pain or discomfort. There is also a very rare risk of seizure associated with the treatment. Patients with metal in or around the head as in metal plates, implants, and stents should not undergo Deep TMS treatment.

REFERENCES:

CDC. Current Cigarette Smoking Among Adults in the United States.

https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking

U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.

Foundation for a Smoke-Free World. Smoking Cessation Products and Services—Global Landscape Analysis.

https://www.smokefreeworld.org/sites/default/files/ey-p_smoking_cessation_landscape_analysis_key_findings.pdf

Zangen A et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021 Oct;20(3):397-404



BrainsWay®

www.brainsway.com